**Practice Guidelines**

**Dyslipidemia Management for Cardiovascular Disease Prevention: Guidelines from the VA/DoD**

### Key Points for Practice
- In primary prevention, moderate-dose statins are recommended when treatment is indicated.
- In secondary prevention, moderate-dose statins are recommended with intensification by increasing statin dose, adding ezetimibe, or adding a PCSK9 inhibitor in higher-risk patients.
- Because cholesterol values are stable over 10 years, new measurements are not needed for each risk assessment.

*From the AFP Editors*

**Cardiovascular disease** caused by atherosclerosis causes significant morbidity and mortality, which can be improved by controlling risk factors through lifestyle interventions and lipid-lowering medications. The U.S. Department of Veterans Affairs and Department of Defense (VA/DoD) have updated recommendations for evaluation and management of dyslipidemia to prevent cardiovascular disease (Figure 1).

### Primary Prevention

Without known cardiovascular disease, treatment decisions should be based on estimated 10-year risk calculators such as the pooled cohort equations ([http://tools.acc.org/ASCVD-Risk-Estimator-Plus](http://tools.acc.org/ASCVD-Risk-Estimator-Plus)). Treatment is recommended at a 10-year risk of 12%, which matches the populations that experienced benefit in clinical trials. People with diabetes mellitus and/or low-density lipoprotein cholesterol levels of at least 190 mg per dL (4.92 mmol per L) are also at high risk and should be offered treatment regardless of estimated risk. Shared decision-making is recommended with 10-year risk between 6% and 12%, which represents populations less studied in clinical trials.

Moderate-dose statins are the sole medication recommended for primary prevention. The group recommends against high-dose statins, citing lack of additional benefit and an increase in risks. The guideline does not suggest one statin over another. Because moderate dosing is recommended for all patients, the guideline does not recommend titrating dosage to a specific cholesterol level. There is no evidence that ezetimibe (Zetia), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, icosapent ethyl, fibrates, bempedoic acid, or niacin is beneficial in primary prevention.

### Secondary Prevention

Patients with known coronary artery disease are at high enough risk to require treatment. Moderate-dose statins are the baseline in this group because no other treatment has a greater impact on mortality. The guideline recommends considering more intense treatment, especially in higher-risk patients. High-dose statin therapy reduced major cardiovascular events in the higher-risk patients studied. Adding ezetimibe to moderate- or high-dose statins reduces nonfatal cardiovascular events to a similar extent as high-dose statins. PCSK9 inhibitors also decrease nonfatal cardiovascular events in high-risk individuals on maximal tolerated therapy to a similar extent. Because of high cost and uncertain long-term safety, PCSK9 inhibitors are recommended only after increasing statin dose and adding ezetimibe. Icosapent ethyl appears to reduce cardiovascular events and mortality with elevated triglyceride levels, although the single trial results are controversial because of...
**FIGURE 1**

Patient ≥ 40 years of age*  

Does patient have heart failure with ejection fraction < 35%, end-stage renal disease, or life expectancy < 5 years?  

No  

Yes  

Discuss lack of evidence demonstrating benefit and continue ongoing care

Does patient have higher-risk CVD? (Sidebar 1)  

No  

Yes  

Recommend stepped intensification:  
Maximize statin or add ezetimibe (Zetia)  
Consider PCSK9 inhibitor only after maximizing statin and adding ezetimibe

Is patient's 10-year CVD risk > 12%?  

No  

Yes  

Recommend moderate-dose statin (Sidebar 3)  
Recommend dietitian-led Mediterranean diet for risk > 12%

Is patient’s 10-year CVD risk 6% to 12% and does patient prefer statin treatment?  

No  

Yes  

Recommend regular aerobic exercise† and smoking cessation (if applicable)

Follow-up evaluation

Primary prevention, no statin:  
Lipid testing every 10 years, recommend nonfasting  
Repeat risk evaluation: every 2 years if 6% to 12%; every 5 years if < 6%; or if risk factors change

Secondary prevention:

Lipids as needed only if higher risk and willing to intensify treatment  
Once taking optimal therapy, no need to recheck lipids routinely

---

*—There are no evidence-based recommendations for patients < 40 years because there is no evidence for the benefit of lipid screening and treatment within this age group. In patients < 40 years interested in pursuing lipid testing and management, shared decision-making is recommended to discuss the risks and unknown benefit of pharmacotherapy, with therapeutic lifestyle changes being the primary focus of CVD primary prevention.

†—Suggest regular aerobic activity of any intensity or duration. Although incremental benefit is associated with increased doses of physical activity, lower doses including leisure time activity (e.g., walking, landscaping, washing dishes) are associated with benefit compared with mostly sedentary behavior. When recommending physical activity, the physician should consider a patient’s motivation, functional capacity, and physical activity preferences.

ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; CVD = cardiovascular disease; MI = myocardial infarction; NA = not applicable; PAD = peripheral arterial disease; PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin/kexin type 9.

**Sidebar 1: Higher-Risk CVD Patients**

MI or ACS in past 12 months; or Recurrent ACS, MI, or CVA; or Known CVD (Sidebar 2) and any of the following: currently smoking, diabetes, PAD, or CABG/PCI

**Sidebar 2: CVD and Equivalents**

MI or ACS  
CABG/PCI  
Stable coronary artery disease (angina or equivalent)  
Atherosclerotic CVA/transient ischemic attack  
PAD (claudication or abdominal aortic aneurysm)  
Does not include asymptomatic incidental finding of potential atherosclerosis (e.g., coronary artery calcium)

**Sidebar 3: Drug Doses**

<table>
<thead>
<tr>
<th>Generic name (brand)</th>
<th>Moderate dose</th>
<th>High dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin (Lipitor)</td>
<td>10 to 20 mg</td>
<td>40 to 80 mg</td>
</tr>
<tr>
<td>Rosuvastatin (Crestor)</td>
<td>5 to 10 mg</td>
<td>20 to 40 mg</td>
</tr>
<tr>
<td>Simvastatin (Zocor)</td>
<td>20 to 40 mg</td>
<td>NA</td>
</tr>
<tr>
<td>Pravastatin (Pravachol)</td>
<td>40 to 80 mg</td>
<td>NA</td>
</tr>
<tr>
<td>Lovastatin (Mevacor)</td>
<td>40 to 80 mg</td>
<td>NA</td>
</tr>
<tr>
<td>Fluvastatin (Lescol)</td>
<td>80 mg (sustained release) or 40 mg twice daily</td>
<td>NA</td>
</tr>
<tr>
<td>Pitavastatin (Livalo)</td>
<td>1 to 4 mg</td>
<td>NA</td>
</tr>
</tbody>
</table>

In patients who are intolerant of statins: after washout (e.g., 1 month), rechallenge with same or a different statin or lower dose, and if that is ineffective, a trial of intermittent (nondaily) dosing.

Intensified patient care (e.g., phone calls, emails, patient education, drug regimen simplification) may improve adherence to lipid-lowering medications.

**Note:** Statin doses listed as moderate are equivalent to moderate intensity; statin doses listed as high are equivalent to high intensity.

---

Algorithm for the management of dyslipidemia for cardiovascular risk reduction.

high rates of cardiovascular events in the control group. Target cholesterol levels are not recommended to guide these decisions.

**Diet**

One diet has clinical evidence of decreasing risk in primary and secondary prevention. A dietitian-led Mediterranean diet decreases rates of cardiovascular events, stroke, type 2 diabetes, and all-cause mortality.

Omega-3 fatty acid supplementation has been studied extensively but does not reduce cardiovascular risk. Fiber, ginger, green tea, garlic, and red yeast rice have been suggested for dyslipidemia, but evidence is insufficient for recommendation.

**Physical Activity**

Physical activity is proven to reduce cardiovascular events. The greatest benefit occurs in sedentary people who pursue limited aerobic physical activity, so no specific target duration is specified.

In the eight weeks following a cardiovascular event or revascularization, structured cardiac rehabilitation has a number needed to treat of 31 to prevent death and myocardial infarction over 10 years.

**Risk Assessment and Monitoring**

In primary prevention, risk assessment in untreated patients is recommended every two years when risk is 6% to 12% and every five years when risk is less than 6%. This risk assessment can use cholesterol levels obtained in the previous 10 years because cholesterol values have been proven stable, with short-term variation more likely because of error. Risk stratification is not improved by additional tests, including coronary artery calcium, high-sensitivity C-reactive protein, and ankle-brachial index.

For patients taking statins, monitoring response by measuring lipid levels is generally unnecessary because titration to a specific cholesterol level is of uncertain benefit. Cholesterol measurement for patients receiving secondary prevention should be limited to only those high-risk patients in whom icosapent ethyl or PCSK9 inhibitors are being considered.

**Excluded Populations**

This guideline focuses on adults 40 years and older. Younger patients have not been studied and generally are at very low risk. Patients with heart failure with an ejection fraction of less than 35% or a life expectancy less than five years are excluded because of limited data that show an absence of benefit from lipid-lowering therapies. Patients with genetic dyslipidemia conditions were also excluded because of limited evidence to guide treatment.

The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Uniformed Services University of the Health Sciences, Department of Defense, Department of Veterans Affairs, or the U.S. government.

**Guideline source:** U.S. Department of Veterans Affairs and Department of Defense

**Evidence rating system used?** Yes

**Systematic literature search described?** Yes

**Guideline developed by participants without relevant financial ties to industry?** Yes

**Recommendations based on patient-oriented outcomes?** Yes

**Available at:** https://www.healthquality.va.gov/guidelines/CD/lipids/

Michael J. Arnold, MD
Uniformed Services University of the Health Sciences
Bethesda, Md.
Email: michael.arnold@usuhs.edu

Andrew Buelt, DO
Bay Pines Veterans Affairs Medical Center
Bay Pines, Fla.
Email: andrew.buelt@va.gov

Editors Note: Drs. Arnold and Buelt are members of the 2020 VA/DoD Dyslipidemia Guideline Working Group.